Background/Objectives: This study was aimed to assess the beneficial effects on metabolic syndrome of functional yogurt NY-YP901 (Namyang Dairy Product Co. Ltd and Nutra R&BT Inc., Seoul, Korea) supplemented with mixture of Streptococcus thermophilus, Lactobacillus acidophilus, Bifidobacterium infantis and extra-ingredients containing Bifidobacterium breve (CBG-C2), Enterococcus faecalis FK-23, fibersol-2 and so on. Subjects/Methods: This study was designed as an 8-week randomized, double-blind, placebo-controlled, parallel study. Treatment and control groups consumed a functional yogurt NY-YP901 (150 ml) and a placebo yogurt twice a day, respectively, for 8 weeks. Body weight and body mass index (BMI), blood pressure, lipid profiles, fasting glucose with HbA1C and waist circumference were measured before and after treatment. Inclusion criteria were healthy individuals between the ages 20-65 years old who submitted an informed consent. Results: During the period August 2009 to December 2009, 101 healthy participants (31 males and 70 females) finished the study. Treatment group were 53 individuals, and the control group were 48 individuals. In the treatment group consuming NY-YP901, statistically significant beneficial changes were observed in body weight (treatment group vs control group-À0.24 ± 1.50 vs þ 0.64 ± 1.39 kg, Po0.05), BMI (À0.10 ± 0.58 vs þ 0.24 ± 0.50 kg/m 2 , Po0.05 ) and low-density lipoprotein (LDL)-cholesterol (À7.71±14.14 vs À0.43±15.32 mg/dl, Po0.05) after 8 weeks. The change in other parameters was not different between the treatment and the control groups. Conclusions: The functional yogurt NY-YP901 reduced LDL-cholesterol, body weight and BMI in the subjects at a 300-ml consumption daily for 8 weeks. From these findings, regular intake of functional yogurt NY-YP901 may be consequently related to improve metabolic syndrome.
Introduction
Recent concerns about metabolic syndrome are increased because many studies identified metabolic syndrome as a multiplex risk factor for cardiovascular disease that is deserving of more clinical attention. The NCEP-ATP III (National Cholesterol Education Program's Adult Treatment Panel III report) identified six components of the metabolic syndrome that relate to cardiovascular disease: (1) abdominal obesity, (2) atherogenic dyslipidemia, (3) raised blood pressure, (4) insulin resistance with glucose intolerance, (5) pro-inflammatory state, and (6) . Currently, oral consumption of fermented dairy products containing probiotics has been associated with prevention, alleviation or cure of diverse intestinal disorder such as lactose intolerance, acute diarrhea, constipation, inflammatory bowel disease and food allergy (Goldin and Gorbach, 2008) . A number of commercial yogurts available in the market are the easiest way to ingest probiotics. In spite of these merit and accessibility of yogurts, some people hesitate to intake yogurt for fearing that yogurt contain high-fat contents and high calory. However, several recently introduced yogurt containing probiotics are known for improving some metabolic parameters as hypertension, hypercholesterolemia beyond gastrointestinal health (Pereira and Gibson, 2002; Liong, 2007; Lye et al., 2009) . Also, adding functional food supplements to yogurt may improve metabolic disorders and have synergic effect with probiotics (Inoue et al., 2003; Miguel et al., 2006; Jauhiainen and Korpela, 2007; Pfeuffer and Schrezenmeir, 2007; Kishimoto et al., 2009) . Accordingly, we have developed functional yogurt NY-YP901 supplemented with mixture of Streptococcus thermophilus, Lactobacillus acidophilus and Bifidobacterium infantis, and functional ingredients containing fibersol-2, FK-23, pine tree leaf extract solution, Peptigen IF-3090, RGP-HC-90, Bifidobacteria producing conjugated linoleic acid (CLA) and YQ-2 and so on, which are supposed to have effects on lowering blood cholesterol, blood sugar, blood pressure and body fat (Blankson et al., 2000; Kim et al., 2003; Lee et al., 2005; Miguel et al., 2006; Kishimoto et al., 2007; Liong, 2007; Shimada et al., 2009) . The aim of our study was to investigate whether functional yogurt NY-YP901 has beneficial effects on the traits of metabolic syndrome, namely body weight, blood pressure, blood glucose and lipid profile during an 8-week intervention period.
Subjects and methods

Subject
Inclusion criteria were healthy, 20-to 65-year-old volunteers. Exclusion criteria were (1) using currently anti-hypertensive drug, lipid lowering drug, oral hypoglycemic agent or insulin; (2) having malignancy, significant cardiac, renal, hepatic and endocrine diseases; (3) adverse reaction to milk products such as lactose intolerance; (4) body mass index (BMI) 430 or o18 kg/m 2 ; (5) taking drug possibly cause glucose intolerance or dyslipidemia; and (6) systolic blood pressure X140 mm Hg or diastolic blood pressure X90 mm Hg, fasting blood glucose X126 mg/dl, dyslipidemia requiring immediate drug therapy according to 2005 revised NCEP-ATP III guideline. In all, 103 eligible subjects were enrolled into the study and randomized into two groups. During the intervention period, two subjects were dropped out due to difficulty adhering to sample collection requirement, 101 subjects completed the study and included in statistical analysis.
Study design
This was a randomized, double-blind, placebo-controlled study in two parallel groups over a period of 8 weeks between August 2009 and December 2009. The volunteers were randomly allocated to receive daily two bottles of either placebo or functional yogurts NY-YP901, respectively. The randomization list and packing yogurt was performed by a person without any practical involvement in the study.
At enrollment, the participants received verbal and written information about the aim of the study, inclusion and exclusion criteria. They were instructed to maintain their eating pattern, level of physical activity, smoking and alcohol habits as before the study. They were also instructed to avoid any kinds of fermented milk products and probiotics supplements 1 week before and during 8 weeks intervention. During an 8-week study period, treatment group consumed a functional yogurt NY-YP (150 ml) twice a day and control group consumed placebo yogurt in the same way as the treatment group. Every day during intervention, the participants filled in diary recording eating pattern including yogurts consumption, well-being, physical activity, bowel habit change and use of medicine.
In week 0 and week 8, the body weight, height, BMI, waist circumference and blood pressure were measured by well-trained nurse and blood sample was drawn in the morning after 10 h of fasting. For the body weight and height, the same digital scale was used each time (Kiker Plus GL-310, G-Tech International Co. Ltd, Seoul, Korea). Waist circumference was measured midway between the distal border of the lowest rib and superior border of the iliac crest at the end of a normal expiration. A manual mercury sphygmomanometry was used to measure blood pressure in the sitting position after 10 min rest period. During 1 h preceding measurement, the subjects were required to refrain from consuming caffeine or smoking, taking any medicine. Blood pressure was measured by three times; median systolic and diastolic blood pressure value was recorded. The subjects rested on a bed in the supine position for 10 min before the blood sample was taken, and the blood was collected in tube without anti-coagulants. Total cholesterol (TC) (enzymatic colorimetric method), high-density lipoprotein (HDL)-cholesterol (modified enzymatic method), low-density lipoprotein (LDL)-cholesterol (direct surfactant method), total triglyceride (TG) (enzymatic colorimetric method), plasma fasting glucose (hexokinase method), HbA1C (high performance liquid chromatography) were measured using automated Hitachi clinical analyzer 7600 (Hitachi, Ltd, Tokyo, Japan) at the Department of Laboratory Medicine, Samsung Medical Center, Seoul, Korea.
The study protocol was approved by Institutional Review Board of Samsung Medical Center according to an ethnic principle and experimental plan based on the Helsinki Declaration. All subjects provided written, informed consent before participation in the study.
Functional yogurt; NY-YP901
The functional yogurt NY-YP901 and placebo yogurt were produced by Namyang Dairy Product Co. Ltd (Seoul, Korea). The raw milk was mixed with skimmed milk powder, and fermented with three starter-S. thermophilus, L. acidophilus, B. infantis-at 36-38 1C for 7-9 h after adding lactase. Each functional yogurt contained S. thermophilusX3 Â 10 9 c.f.u./g, L. acidophilusX3 Â 10 9 c.f.u./g, B. infantisX1 Â 10 10 c.f.u./g (MSK-B2; Danisco Deutschland GmbH, Germany) and functional ingredients such as fibersol-2 (resistant maltodextrin; Matsutani Chemical Industry Co., Ltd, Itami, Japan), FK-23 (Enterococcus faecalis FK-23; Nichinichi Pharmaceutical Co., Ltd, Tokyo, Japan), extract from pine needle (Pinus densiflora Seib et Zucc.; S&D Co., Ltd, YeonGi-Gun, Korea), peptigen IF-3090 (whey protein hydroxylate; Arla foods ingredients amba, Skanderborg, Denmark), RGP-HC-90 (Rice germ extract powder; Oryza Oil&Fat Chemical Co., Ltd, Ichinomiya, Japan) Bifidobacterium breve (Chebigen Co., Ltd, Jeonju, Korea) and YQ-2 (Yucca schidigera and Quillaja saponaria extract; Celltechs Co., Ltd, Seoul, Korea) in 150 ml. The control yogurts contained the same ingredients of S. thermophilus, L. acidophilus, B. infantis except functional ingredients. The contents of calorie, water, fat, protein, carbohydrate and electrolytes were comparable in both products and bottles of yogurts were of same size, shape. The nutritional content of test and the placebo yogurt are shown in Table 1 .
Statistical analysis
Comparisons of baseline anthropometrics and blood sample results between functional and control yogurt group were made using independent t-tests and Mann-Whiney test. Within-group baseline vs end-of-study changes in parameters (body weight, waist circumference, BMI, blood pressure, blood glucose, HbA1c and lipid profiles) was evaluated with paired t-tests, and independent t-tests were used to assess differences in baseline vs end-of-study change in parameters between groups. A P-value o0.05 was regarded statistically significant. Statistical analysis was performed by SPSS statistical software (version 17.0, SPSS Inc., Chicago, IL, USA).
Results
The 53 subjects in functional yogurt NY-YP901 group consisted of 16 men and 37 women (mean age: 36.5 ± 9.9 years) and 48 subjects in the placebo yogurt group consisted of 15 men and 33 women (mean age: 37.2±8.9 years). There were no significant differences in the anthropometric variables including blood pressure, baseline lipid profile (LDL, HDL, TC, TG), fasting blood glucose and HbA1C level in both the groups (Table 2 ). The change in variable parameters during intervention was summarized in Table 3 . Compared with the changes in the control group, body weight (À0.24± 1.50 kg, P ¼ 0.006) and BMI (À0.10±0.58 kg/m 2 , P ¼ 0.006) were decreased in functional yogurt NY-YP901 group. However, there were no significant differences of changes in waist circumference, systolic and diastolic blood pressure, fasting blood glucose, HbA1c, TC, HDL, TG between the two groups, and within group. Interestingly, the LDL-cholesterol level decreased significantly different from baseline by 7.71±14.14 mg/dl in functional yogurt group after 8 weeks (P ¼ 0.000, paired t-test), and the decrease of LDL-cholesterol was 0.43 ± 15.32 mg/dl after 8 weeks in the control group (P ¼ 0.844, paired t-test). The difference in change of LDL-cholesterol between the two groups was significant (P ¼ 0.044, independent t-test).
Discussion
The major finding of the present study was a decrease of LDL-cholesterol after 8 weeks in functional yogurt group as compared with control group. The decrease in LDLcholesterol amounted to 7.71 ± 14.14 mg/dl. The reason for observed cholesterol lowering effect is proposed to either YQ-2, fibersol-2 and pine tree leaf extraction solution among functional ingredients or synergic effect of functional ingredients and probiotics. YQ-2 is saponin a natural detergent found in many plants, but extracts from Y. schidigera and Q. saponaria are currently commercially available. Taking 0.9 mg of YQ-2 a day for 4 weeks resulted in the decrease in TC and LDL-cholesterol levels in blood plasma of hypercholesterolemic patients with enhancement in gastrointestinal symptoms in patients (Kim et al., 2003) . The mechanism of YQ-2 on cholesterol lowering effect was not clearly understood. But previous study suggested that saponin bound to the digested lipid, bile acid and became the insoluble unabsorbed form, and then excreted as stool. Under these conditions, reduction in hepatic cholesterol induced compensatory increases in both hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and hepatic LDL receptor (Harwood et al., 1993) .
Fibersol-2 (resistant maltodextrin) is obtained by heating corn starch with a small amount of hydrochloric acid, following enzymatic hydrolysis with a-amylase and glucoamylase, and fraction of dietary fiber (Fastinger et al., 2008) . The mechanism of resistant maltodextrin for improving lipid profile is suggested that it hinders small intestine from absorption of lipid, which results to promoting lipid excretion into feces by delaying the release of fatty acids from micelles in the lipid absorption process (Kishimoto et al., 2009) . As for resistant maltodextrin, its suppressive effect on postprandial rise in triacylglycerol was observed in animal and human studies (Kishimoto et al., 2007 (Kishimoto et al., , 2009 ). Postprandial elevation of blood triglyceride is known to relate closely to the development of arteriosclerosis and coronary artery diseases, which are the major contributors for metabolic syndrome (Rapp, 2002; Le and Walter, 2007) . The slight downward trend in TG was observed in functional yogurt group compared with controlled group in our study.
The pine tree is an evergreen, needle-leafed tree, widely distributed through East Asia including Korea, Japan and Northeastern China. Various parts of the tree, that is, needles, cones, cortices and pollen, have been widely used as folk medicine or as food to promote health . The pine needle is rich in polyphenols, terpenoids and tannin. In vitro studies, extract of pine needle decreased TC and TG, alcohol-related liver cell damage and inhibit a-glucosidase enhancing anti-diabetic effect. And, it is also reported to have beneficial effect to control obesity (Kim et al., 2005; Lee et al., 2005; Jeon and Kim, 2006; Yim et al., 2006) . Pine needle extract supplement significantly reduced plasma TG and TC (Jeon and Kim, 2006) , and TG levels may be reduced to below normal level with regular administration of pine oil (Jeon and Kim, 2006) . The reason on cholesterol lowering effect on pine needle extract was not clear yet, proanthocyanidin in polyphenol may repress intestinal lipid absorption, chylomicron secretion by the intestine and very-low-density lipoprotein secretion by the liver (Blade et al., 2010) .
Cholesterol lowering effect of probiotics, which Lactobacillus and Bifidobacterium genera, S. thermophilus and Enterococcus faecium have been mostly used, has raised much interest. In vitro experiments have suggested several mechanisms for the cholesterol lowering effect of probiotic bacteria (Liong, 2007) . Bacteria may directly remove cholesterol by incorporating it into the bacterial cell membrane, binding cholesterol to the cell surface or assimilating cholesterol during growth. In addition, bacteria may produce bile salt hydrolase and deconjugate bile acids. The resulting bile acids coprecipitate with cholesterol and are excreted in the feces, thereby reducing cholesterol through fecal excretion and through the synthesis of additional bile acids from cholesterol. Xiao et al. (2003) found that milk fermented by Bifidobacterium longum BL1 reduced serum TC, LDL-cholesterol and TG not only in rats, but also in hypercholesterolemia patient and healthy adults. But, investigations demonstrating a cholesterol lowering effect have generally been conducted in subjects with moderately elevated (46.0 mmol/l) baseline TC, in vivo trial aimed at evaluating the cholesterol lowering effect of consuming probiotics have yielded inconstant data (Pereira and Gibson, 2002; Kim et al., 2005) . Such contradictory results could be related to experimental design, lack of statistical power, use of inadequate sample size, failure to control nutrient intake and energy expenditure during the experiments or variation in the baseline levels of blood lipids. In the present study, the subjects were relatively young adults, free from chronic underlying disease and normocholesterolemic. The subjects were instructed to maintain their lifestyle; however, we could not control definitely dietary pattern, physical activity, tobacco and so on. Although the control yogurt containing probiotics without functional ingredients did not show cholesterol lowering effect in our study, probiotics may have supplementary effect with functional ingredient in group consuming the functional yogurts.
After 8 weeks intervention, a small decrease in body weight (À0.24 ± 1.50 kg) was found in functional yogurt. However, the differences in changes in body weight between the two groups was statistically significant (P ¼ 0.006). Because the eating pattern was not significantly different according to diet records during intervention, this weight reduction effect after intake 190 Kcal with yogurt daily is worthy of attention if there were no meaningful inaccuracies in dietary records. Previous study with probiotic milk product showed body weight gain during an 8-week intervention (Agerholm-Larsen et al., 2000) . The reason for this result was not clear, but it seems to be associated with whey protein, pine leaf extraction and Bifidobacterium producing CLA. Peptigen IF-3090 is whey protein hydrolysates, which have potential to contribute to the regulation of body weight by providing satiety signals that affect food intake regulation (Luhovyy et al., 2007) . Furthermore, whey protein is insulinotropic and whey-born peptides have angiotensin I-converting enzyme inhibitor activity, so nowadays whey protein has been introduced as functional food component for person with obesity and its comorbidities (hypertension, type II diabetes, dyslipidemia) (Kawase et al., 2000; Frid et al., 2005) .
The role of individual whey proteins and peptides in contributing to food intake regulation has not been fully defined, but, whey protein reduces short-term food intake relative to placebo, carbohydrate and other proteins. In vitro study showed pine leaf extraction supplement significantly decreased body weight gain and visceral fat mass in rats fed high-fat diet (Jeon and Kim, 2006) . Their results indicate that pine needle extract suppresses adipocyte differentiation, in part through a mechanism of peroxisome proliferatoractivated receptor-g mediated adipogenesis, and may have the potential to produce anti-obesity effects. CLA is a general term that refers to a set of positional and geometric conjugated isomers of linoleic acid. In several studies, CLA has been shown to reduce body fat, CLA-induced changes have been associated with increased lipolysis in adipocytes and enhanced fatty acid oxidation in both adipocyte and skeletal muscle cells (Blankson et al., 2000; Kennedy et al., 2010) .
This controlled study showed that regular consumption of functional yogurt has no effect on blood pressure in normal blood pressure subjects. In fact, we expected to see decrease in blood pressure after 8 weeks because functional yogurt contained E. faecalis FK-23, whey protein and g-aminobutyric acid (GABA), which are supposed to have effects on lowering blood pressure (Kawase et al., 2000; Hayakawa et al., 2002; Miguel et al., 2006) . FK-23 is a strain of E. faecalis, normal gastrointestinal flora. Previous studies showed that RNA fraction in the soluble heat extract of E. faecalis FK-23 has selective anti-hypertensive effect on spontaneously hypertensive rats (Miguel et al., 2006) . RGP-HC-90 is GABA extracting from rice germ. GABA is available from many vegetables and fruits, which have been reported to reduce blood pressure in experimental animals and human (Inoue et al., 2003) . Anti-hypertensive effect of GABA is partially due to its ability to inhibit sympathetic nerve activity (Hayakawa et al., 2002; Okita et al., 2009) . We have no obvious explanation for this finding. One possible explanation for missing effect could be the degree of blood pressure between studies. Previous study with whey protein and GABA mostly showed blood pressure lowering effect on the group with mild hypertension or high normal blood pressure (Inoue et al., 2003; Seppo et al., 2003; Shimada et al., 2009) . Other explanation could be degradation of peptides by intestinal or plasma peptidases before they could exert an effect on blood pressure, insufficient absorption, low dosage and short duration. And to examine exactly the blood pressure lowering effect of these ingredients and probiotics, 24 h ambulatory blood pressure monitoring may be appropriate on behalf of median value of temporal blood pressure.
In conclusion, the functional yogurt was associated with decreased LDL-cholesterol and body weight, BMI after daily consumption of 8 weeks. Although there was no significant effect on the parameters of metabolic syndrome such as blood pressure, fasting blood glucose, TG and HDL, the decreases in LDL-cholesterol and body weight were expected to decrease cardiovascular risk. Further study will be needed for individual functional ingredients that are expected to have cholesterol lowering effect and weight reduction effect in present study.
